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Background: Regulatory and economic frameworks stimulated the research and development of orphan drugs,
but very little has been done for devices necessary for the in-vivo diagnosis, prevention and treatment of life-
threatening conditions with a low prevalence/incidence.
Discussion: A general public consultation in Europe has shown a positive attitude towards an “orphan device”
directive. The United States of America have a Humanitarian Use Device exemption, but Europe is still waiting for
such a stimulating framework. Post-marketing surveillance (“materio-vigilance”) will be necessary for follow-up,
patient-reported outcome measures (quality of life versus survival) needed and off-label use data available for
patient-safety reasons.
Summary: The marketing period for devices is shorter than for medicinal products. Incentives are necessary to
stimulate research and development of such “orphan devices” especially when surgical intervention is the only
option.
Keywords: History of medicine, Rare diseases, Orphan drugs, Custom-made medical devices, Humanitarian-use
devices
Orphan devices are medical devices intended for the in-
vivo diagnosis, prevention or treatment of a very rare
life-threatening or chronically debilitating condition.
Several institutions (for example, the United States Food
and Drug Administration (FDA), the European Medi-
cines Agency (EMA), and the Australian Therapeutic
Goods Administration (TGA)) have put in place regula-
tory and economic frameworks to facilitate the develop-
ment of orphan drugs (118 authorized by EMA to date),
but much needs to be done for similar medical devices,
especially in Europe. Do we need an EU-directive for or-
phan devices?
Historical background
During the twentieth century, several breakthroughs in
surgery were achieved [1]. For example, Alfred Blalock
(1899–1964) developed a surgical procedure in 1944 to
relieve the cyanosis in the Blue Baby Syndrome, a kidney
was transplanted between identical twins in 1954, and a
liver transplantation was performed in 1963 by Thomas
Starzl (°1926). Numerous new techniques were devel-
oped such as direct blood transfusion by George
Washington Crile (1864–1943) in 1905, amniocentesis
in 1952 by Douglas Bevis (1919–1994), and diagnostic
ultrasound by Ian Donald (1910–1987) in 1958.
New “innovative” instruments were also devised to
save the lives of patients with low-prevalence diseases.
But without any incentive it took the developers years in
the past to get these life-saving instruments to the mar-
ket. I will describe a few such cases here.
1. The negative pressure ventilator (“Iron Lung”)
A negative pressure ventilator (“Iron Lung”) is a med-
ical ventilator that enables a patient to breathe when
spontaneous breathing control has been lost or exceeds
the patient’s ability. This device was invented by Philip
Drinker (1894–1972) and Louis Agassiz Shaw (1886–
1940) at the Harvard School of Public Health after an
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idea of John Dalziel in 1832. The first clinical use (12
October 1928) was with an 8-year-old girl with respira-
tory failure due to poliomyelitis. The patient was placed
in a cylindrical steel drum. A door allowing the head
and neck to remain free (left at Fig. 1) was then closed,
forming a sealed, air-tight compartment enclosing the
rest of the body. Pumps (lower right at Fig. 1) periodic-
ally decrease and increase the air pressure within the
chamber and particularly on the chest. When the pres-
sure is less than that within the lungs, the lungs expand
and atmospheric pressure pushes air in. When the pres-
sure goes above that within the lungs, the air is expelled
[2]. This device is also used for Ondine’s curse and other
rare conditions in which failure of the medullary respira-
tory centers in the brain results in patients having no
autonomic control of breathing. Poliomyelitis vaccina-
tions (Jonas Salk 1952) have virtually eradicated new
cases of poliomyelitis, and the iron lung has virtually dis-
appeared from modern medicine.
2. Stereotactic brain surgery
Stereotactic brain surgery was devised as a minimally
invasive form of surgical intervention in the human
brain that uses a three-dimensional coordinate system to
locate small targets inside the brain and to perform
some action such as injection and/or stimulation. The
patient, under local anesthesia, sat on a chair (Fig. 2)
and the mechanical head-holding clamps and bars kept
the head of the patient in a fixed position in reference to
the coordinate system. The stereotactic method was first
developed in 1908 at the University College London
Hospital by a British neurosurgeon, Victor Horsley
(1857–1916), and the physiologist Robert H Clarke. This
technique was the start of neuro-stimulation and
evolved also to Deep Brain Stimulation (DBS), and
neurosurgical methods for patients with rare forms of
Parkinson’s disease, obsessive compulsive disorders,
hyperkinesia, dystonia and convulsive diseases. In 2007,
the EMA approved Gliolan (5-aminolevulinic acid oral
solution) as an orphan drug to localize the tumor during
brain surgery: when illuminated under blue light, the
tumor cells glow an intense red when Gliolan is taken
orally, while the normal brain tissue appears blue.
3. Incubator
An incubator (“isolette”) is an apparatus used to main-
tain environmental conditions suitable for a neonate: a
sufficiently humidified and heated environment. It was
used in preterm births or some ill full-term babies some-
times with a rare disorder. Stephane Tarnier (1828–
1897) is generally considered to have been the father of
the incubator, which he developed in a Paris maternity
ward [3]. Oxygen was given freely (Fig. 3) until the end
of the 1950’s when it was shown that the high concen-
trations reached inside incubators sometimes caused ba-
bies to go blind. Early incubators were even shown at
commercial exhibitions with babies inside (Exposition
Universelle de Bruxelles 1897: “Une visite aux couveuses
d’enfants ne s’oublie jamais”). Since the Second World
War, special-care baby units were established all over
Fig. 1 The negative pressure ventilator (“Iron Lung”)
Fig. 2 Stereotactic brain surgery
Fig. 3 Incubator
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the world to provide neonatal care. The EMA authorized
several orphan drugs to be used in neonatology such as
Pedea (ibuprofen) for the treatment of hemodynamically
significant patent ductus arteriosus in preterm newborn
infants in 2004 and Peyona (caffeine) for the treatment
of primary apnea in premature newborns in 2009.
4. Dialyzer
The Dutch physician Willem Johan Kolff, (1911–2009)
constructed the first working dialyzer in 1943 inspired
by a scientific article from 1913 of John Abel. Nils Alwall
(1904–1986) modified his construction later by enclos-
ing it inside a stainless steel canister [4]. He treated his
first patient, suffering from acute renal failure, on
September 3, 1946. The blood contained in the 30 wind-
ings of cellophane tube which was plainly visible (Fig. 4).
The cylinder was provided with ridges. Over the years
this large machine was miniaturized (“wearable artificial
kidney” or hemofiltration) and is now used in the treat-
ment of some patients with end-stage renal disease.
Some patients perform peritoneal dialysis at home. Pro-
cysbi (cysteamine bitarate caps), a controlled release
form of Cystagon, was authorized in 2013 by EMA to
delay the development of renal failure in patients with
nephropathic cystinosis.
5. Orthopedic traction table
Orthopedic surgery was originally restricted to the
correcting of musculoskeletal deformities in children
such as clubfoot and curvatures of the spine. Spine ex-
tension methods are being used since antiquity and a
traction table was described by Hippocrates (460–370
BC). The internal fixation of fractures was made possible
with the development of orthopedic traction tables [5]
(see Fig. 5). The bones of patients with Osteogenesis
imperfecta (also known as the Brittle Bone Disease or
the Lobstein Syndrome) were surgically corrected and
rods were placed inside the bones to enable them to
learn to walk. Dr. E A Miller described the process in
1959.
Operating theaters now have a large collection of ster-
ile medical material to be implanted during surgical in-
terventions such as neuro-stimulators, prostheses, heart
valves, stents, osteosynthesis material and pacemakers.
All this material is evaluated by “notified bodies” in
every EU-Member State (Regulation 93/42/EEC from 14
JUNE 1993 concerning medical devices and Regulation
90/385/EEC concerning implantable active medical de-
vices) and assigned a CE (Conformité Européenne)
marking when approved. Different systems have also
been used to evaluate post-marketing the efficacy and
safety (“materio-vigilance”, Eudamed) of such devices.
The use of a medical device outside the population or
purpose for which the safety and effectiveness profile
has been evaluated (off-label use) is quite common with
low-prevalence diseases (mainly in children). To encour-
age the research into, and development of, medical ma-
terial (“orphan devices”) for the in-vivo diagnosis,
prevention and treatment of rare diseases we do need in-
centives such as a centralized European procedure and
protocol assistance. This is of particular urgency because
the marketing period for devices is shorter than for me-
dicinal products: the risk on obtaining no return on in-
vestment for R & D on devices is real. The absence of
incentives will become more important as we continue
to enter the era of personalized medicine with the cap-
abilities of bio-sensors, micro-fluidic tissue/organs on a
micro-chip, artificial organs and diagnostic imaging
instruments.
Actual opinions within EU member states
A general public consultation of the European Com-
mission (2007) has been launched to find out if the
EU should have an orphan regulation on medical de-
vices and diagnostics [6] (Question 9). Hundreds of
Fig. 4 Dialyzer
Fig. 5 Orthopedic Traction Table
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responders (patients and their families, national and
international (patient) organizations, national authorities,
commercial organizations and companies, universities and
experts, reference centers and researchers) were in favor
of such a regulation except the following six:
*The Association Internationale de la Mutualité
thought there is neither enough information nor
evidence to justify it.
*The European Social Insurance Platform mentioned
that medical devices already on the market were not
specific to “rare disease”.
*The UK National Health Service stated that they did
not believe that there were sufficient problems in the
development and commercial marketing of devices to
justify the administrative effort and special privileges
for orphan regulations.
*The Ministry of Health, The Elderly and Community
Care in Malta felt that such a regulation would neither
be necessary nor beneficial and that the current legal
framework already provided stimulation for rare
diseases.
*The Dutch Ministry of Public Health, Welfare and
Sports, Drugs and Medical Technology considered a
EU regulation in this matter not the right way forward
as there are different reimbursement systems within
the different EU Member States.
*Baxter Healthcare did not see any justification to
introduce such legislation.
Of all the overwhelmingly positive reactions, I cite
only a few here:
*The Finnish rare-disease patient organization replied
to this question of the consultation that developing
equipment and determining norms in the EU would
help those countries who still have challenges to im-
prove their national standards. The ability to improve
the national standard was considered insufficient in
many EU countries and the markets too small.
*The Swedish government agreed that there was a need
to investigate the conditions required for developing
incentive measures and legislation for orphan devices
similar to orphan drugs, but they suggested a thorough
analysis of the financial impact and possible rules
should first take place.
*The UK Genetic Interest Group (patients) suggested
that the burden of regulation should be kept to a
minimum with a single European application.
Nevertheless, “orphan-device” legislation has yet to be
introduced in Europe today [7] as we have for orphan
medicinal products since 2000. Only some EU Member
States have national rules (for Belgium: Royal Decrees
15 July 1997 and 18 March 1999) for medical devices
(“dispositif à usage unique”).
In the United States of America a Humanitarian Use
Device (HUD) [8, 9] is a device that is intended to bene-
fit patients by treating or diagnosing a disease or condi-
tion that affects or is manifested in fewer than 4000
individuals in the United States per year. The application
(since 1990) must contain sufficient information for the
FDA to determine that the device does not pose an un-
reasonable or significant risk of illness or injury and that
the probable benefit to health outweighs the risk of
injury or illness from its use taking into account the
probable risks and benefits of currently available devices
or alternative forms of treatment. Up to the present, 65
HUD’s have been approved by FDA, mostly implantable
(programmable) therapeutic devices in pediatrics
(pediatric devices) [10], cardiology (ventricular assist
devices in congestive heart failure) [11], neurology
(microelectrodes for neurostimulation), hematology
(cryofilter for cryofiltration apheresis) [12], otorhino-
laryngology (auditory brain stem implants) and orthope-
dics (craniosynostosis).
Custom made (active implantable) medical devices are
devices that are made by special request (eventually 3D-
printed) of a health professional intended to be used for
a particular patient [13]. Several agencies (UK, TGA,
FDA) [14] have regulations in place to allow the use of
these unique one-time devices foremost in unmet
medical need situations. Technological changes, im-
provements and refinements provide a much shorter
marketing period to obtain revenue to develop newer
versions of the device.
Position: policy recommendation
A regulatory European framework with economic incen-
tives needs to be installed to stimulate the research and
development of orphan devices similar to the legislation
around orphan drugs. Incentives are needed (as for or-
phan drugs) to enable useful medical devices to reach
the patients and clinicians in a timely fashion. Collection
and analysis of publicly accessible safety/efficacy data
(EUDAMED: European Databank on Medical Devices)
needs to be centralized between all EU Member States
to reach a sufficient number of patients to perform com-
parative-(cost)effectiveness and –safety studies.
All pictures are taken from the archives of HistArUz,
the Museum of the History of Medicine and Pharmacy
at the University Hospitals Leuven, Belgium: http://
www.uzleuven.be/histaruz.
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